IN-10018 is under clinical development by InxMed (Beijing) and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IN-10018’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IN-10018 (BI-853520) is under development for the treatment of peritoneal cancer, fallopian tube cancer, advanced or metastatic non-hematologic malignancies including metastatic adenocarcinoma of the pancreas, advanced or metastatic triple-negative breast cancer (TNBC), recurrent and/or metastatic head and neck squamous cell carcinoma, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma, platinum-resistant ovarian carcinoma, oesophageal carcinoma of adenocarcinoma, soft tissue sarcoma, gastric cancer, metastatic uveal melanoma, metastatic melanoma, non-small cell lung cancer and head and neck cancer, solid tumors, pancreatic ductal adenocarcinoma and advanced or metastatic pancreatic cancer. It is a small molecule administered orally. The drug candidate acts on protein tyrosine kinase 2 (focal adhesion kinase). It was under development for non-hematologic malignancies and solid tumor.
InxMed (Beijing) overview
InxMed (Beijing) (InxMed) operate in healthcare sector focusing on research and development of drugs for the tumor fibrosis microenvironment. InxMed is headquartered in Beijing, China.
For a complete picture of IN-10018’s drug-specific PTSR and LoA scores, buy the report here.